Confocal Endomicroscopy in Urologic Surgery: urothelial carcinoma and other emerging applications

Similar documents
Interobserver Agreement of Confocal Laser Endomicroscopy for Bladder Cancer

Author's Accepted Manuscript

Confocal Laser Endomicroscopy of Bladder and Upper Tract Urothelial Carcinoma: A New Era of Optical Diagnosis?

Controversies in the management of Non-muscle invasive bladder cancer

INCREASE DETECTION, REDUCE RECURRENCE. NBI Is Clinically Proven to Diagnose More Bladder Cancer

Clinical Policy Title: Enhanced cystoscopy for bladder cancer

Chromoendoscopy and Endomicroscopy for detecting colonic dysplasia

ARTICLE IN PRESS. tumor grade or stage information. Procedures

Computer aided optical diagnosis of polyps. Dr Michael Byrne Vancouver General Hospital University of British Columbia

Diagnosis and classification

Technology and Engineering Dynamic Real-time Microscopy of the Urinary Tract Using Confocal Laser Endomicroscopy

GUIDELINES ON NON-MUSCLE- INVASIVE BLADDER CANCER

Staging and Grading Last Updated Friday, 14 November 2008

KARL STORZ Blue Light Cystoscopy with Cysview System. Photodynamic Diagnosis (PDD)

Upper Tract Urothelial Cancers Nephron Sparing Strategies

Symptoms, Diagnosis and Classification

The Optical Biopsy. Douglas S. Scherr

Issues in the Management of High Risk Superficial Bladder Cancer

Clinical Policy Title: Enhanced cystoscopy for bladder cancer

Upper urinary tract urothelial carcinoma (UTUC)

Introduction. Phil Hyun Song, MD, PhD 1 Seok Cho, MD 2 Young Hwii Ko, MD, PhD 1. pissn , eissn

Non-Muscle Invasive Bladder Cancer BCG Failures: University of Iowa Hospitals and Clinics Experience. Paul Gellhaus Assistant Clinical Professor

Renal biopsy is mandatory for every small renal mass

Transurethral resection of bladder tumours: established and new methods of tumour visualisation

Guidelines for the Management of Bladder Cancer West Midlands Expert Advisory Group for Urological Cancer

Pathologic Assessment of Invasion in TUR Specimens. A. Lopez-Beltran. T1 (ct1)

Validation of Confocal Laser Endomicroscopy Features of Bladder Cancer: The Next Step Towards Real-time Histologic Grading

Citation for published version (APA): Cauberg, E. C. C. (2011). Advancements in diagnostic imaging for urothelial carcinoma.


CYSVIEW. CONFIDENCE AT FIRST SIGHT

Reviewing Immunotherapy for Bladder Carcinoma In Situ

Department of Urology, Cochin hospital Paris Descartes University

Role of Re-Resection in Non Muscle-Invasive Bladder Cancer

BLADDER CANCER: PATIENT INFORMATION

A patient with recurrent bladder cancer presents with the following history:

NMIBC. Piotr Jarzemski. Department of Urology Jan Biziel University Hospital Bydgoszcz, Poland

HOW TO USE HEXVIX. A practical guide for preparation of Hexvix

Confocal Laser Endomicroscopy

Critical Evaluation of Early Post-operative Single Instillation Therapy in NMIBC

RITE Thermochemotherapy in the treatment of BCG refractory NMIBC

Harry W. Herr and S. Machele Donat Department of Urology, Memorial Sloan-Kettering Cancer Center, New York, NY, USA

Diagnosis & Treatment of Non- Muscle Invasive Bladder Cancer: AUA/SUO Guidelines

When to Integrate Surgery for Metatstatic Urothelial Cancers

Decipher Bladder Predicts Which Patients May Benefit from Neoadjuvant Chemotherapy Prior to Radical Cystectomy

Advances in Endoscopic Imaging

Saturday, 13 February 2016

Ureteroscopy Is Indicated in every patient with suspected Upper Tract Urothelial Tumor

Urology An introduction to cut up DR J R GOEPEL

Citation International journal of urology (2. Right which has been published in final f

Haematuria and Bladder Cancer

Joseph H. Williams, MD Idaho Urologic Institute St. Alphonsus Regional Medical Center September 22, 2016

Volumetric laser endomicroscopy can target neoplasia not detected by conventional endoscopic measures in long segment Barrett s esophagus

Application of Urovision FISH testing for diagnosis of bladder cancer

BLADDER CANCER EPIDEMIOLOGY

Clinical significance of immediate urine cytology after transurethral resection of bladder tumor in patients with non-muscle invasive bladder cancer

Kidney, Bladder and Prostate Neoplasia. David Bingham MD

Bladder Cancer Guidelines

Management of Barrett s: From Imaging to Resection

The group seemed largely happy with the proposed GDG membership. Additional comments and clarifications as below:

MUSCLE-INVASIVE AND METASTATIC BLADDER CANCER

FEP Medical Policy Manual

How Many Diseases in Carcinoma in situ?

FEP Medical Policy Manual

American Journal of Gastroenterology. Volumetric Laser Endomicroscopy Detects Subsquamous Barrett s Adenocarcinoma

Is renal cryoablation becoming an effective alternative to partial nephrectomy?

Urological Oncology. Dae Hyeon Kwon, Phil Hyun Song, Hyun Tae Kim.

MUSCLE - INVASIVE AND METASTATIC BLADDER CANCER

Q&A. Fabulous Prizes. Collecting Cancer Data: Bladder, Renal Pelvis, and Ureter 5/2/13. NAACCR Webinar Series

Multiple Primary and Histology Site Specific Coding Rules URINARY. FLORIDA CANCER DATA SYSTEM MPH Urinary Site Specific Coding Rules


Confocal Laser Endomicroscopy. Populations Interventions Comparators Outcomes Individuals: With suspected or known colorectal lesions

3.1 Investigations for Patients Presenting with Haematuria Table 1

5/21/2018. Prostate Adenocarcinoma vs. Urothelial Carcinoma. Common Differential Diagnoses in Urological Pathology. Jonathan I.

A Practicum Approach to CS: GU Prostate, Testis, Bladder, Kidney, Renal Pelvis. Jennifer Ruhl, RHIT, CCS, CTR Janet Stengel, RHIA, CTR

Urinary Bladder: WHO Classification and AJCC Staging Update 2017

Segmental ureterectomy does not compromise the oncologic outcome compared with nephroureterectomy for pure ureter cancer

Contemporary Role of Renal Mass Biopsy

Appendix 4 Urology Care Pathways

Flexible Cystoscopy. The Olympus KeyMed Group of Companies

Predict, Resect and discard : Yes we can! (at least in some hands)

Image Captioning using Reinforcement Learning. Presentation by: Samarth Gupta

University Mainz. Early Gastric Cancer. Ralf Kiesslich. Johannes Gutenberg University Mainz, Germany. Early Gastric Cancer 15.6.

COLON: Innovations 3 steps, 3 parts..

EAU GUIDELINES ON NON-MUSCLE INVASIVE (TaT1, CIS) BLADDER CANCER

Updates in Urologic Pathology WHO Made Those Changes?! Peyman Tavassoli Pathology Department BC Cancer Agency

Second transurethral resection against Ta high grade tumor:residual location and predictive factor. A single center, retrospective study

Classification of breast cancer histology images using transfer learning

Your Chance to Improve Patient Outcome. Narrow Band Imaging (NBI) The New Standard for Diagnostics and Treatment

RAPN. in T1b Renal Masses? A. Mottrie. G. Denaeyer, P. Schatteman, G. Novara

ICUD 2011 Recommendations. Bladder Cancer

Efficacy and Safety of Hexaminolevulinate Fluorescence Cystoscopy in the Diagnosis of Bladder Cancer

Mini-Invasive Treatment in Urological Diseases Dott. Alberto Saita Responsabile Endourologia Istituto Clinico Humanitas - Rozzano

Genitourinary Oncology Fellowship for Physicians in China A Multidisciplinary Clinical and Research Training Opportunity at Massachusetts General

The Impact of Blue Light Cystoscopy with Hexaminolevulinate (HAL) on Progression of Bladder Cancer ANewAnalysis

John Leppert. Associate Professor of Urology and, by courtesy, of Medicine (Nephrology) at the Palo Alto Veterans Affairs Health Care System.

MEDitorial March Bladder Cancer

Treatment of Non-Metastatic Muscle-Invasive Bladder Cancer: AUA/ASCO/ASTRO/SUO Guideline

Skin cancer reorganization and classification with deep neural network

+ use molecular testing to help drive my patients treatment plans.

Transcription:

INTERNATIONAL SOCIETY FOR ENDOMICROSCOPY (IS4E) PARIS, FRANCE NOVEMBER 27, 2017 Confocal Endomicroscopy in Urologic Surgery: urothelial carcinoma and other emerging applications Joseph C. Liao, MD Department of Urology Stanford University

Bladder cancer and UTUC Bladder cancer 5 th most common cancer in the U.S. 75-80% present as non-muscle invasive Ta/T1/TIS High recurrence rate up to 50-70% Upper tract urothelial carcinoma Shares histologic features with bladder ca 5-10% of all urothelial carcinoma Endoscopy integral part of management Tissue diagnosis and local staging Therapy: TUR and ablation Surveillance Jemal et al. CA Cancer J Clin, 2010. 60(5):277-300; Wood et al. Cambell-Walsh Urology, 10 th.ed. 713-25; Roupret et al. Eur Urol. 2013 Jun;63(6):1059-71.

Enhanced cystoscopy in current guidelines 2016 In a patient with NMIBC, a clinician should offer blue light cystoscopy at the time of TURBT, if available, to increase detection and decrease recurrence. (Moderate Recommendation; Evidence Strength: Grade B) In a patient with NMIBC, a clinician may consider use of NBI to increase detection and decrease recurrence. (Conditional Recommendation; Evidence Strength: Grade C) Hexaminolevulinate-assisted blue light cystoscopy (BLC) Narrow band imaging (NBI) Chang et al. 2016. https://www.auanet.org/education/guidelines/non-muscle-invasive-bladder-cancer.cfm

Confocal endomicroscopy Optical biopsy: dynamic in vivo confocal microscopy (488 nm) Approved for clinical use in Europe and U.S. (2015) Cellvizio, Mauna Kea Technologies Fluorescein as contrast agent Intravesical or intravenous route Probe-based (0.85 to 2.6 mm) Real time visualization of cancer microarchitecture and cellular features Sonn et al. J Urol. 2009. 182(4):1299-1305; Adams et al. J Endourol. 2011. 25(6):1-5; Wu et al. Urology, 2011. 78(1):225-31.

Endomicroscopy of bladder cancer optical imaging atlas Chen et al. (2014) Curr. Urol Rep. 15:437; Hsu et al. (2014) Cur Opin Urol. 24:66; Chang et al. (2013) J Endourol. 27(5):598-603

Interobserver Agreement TABLE 3. INTEROBSERVER AGREEMENT AND DIAGNOSTIC ACCURACY FOR CANCER DIAGNOSIS CLE WLC WLC + CLE Interobserver Agreement pa κ (95% CI) pa κ (95% CI) pa κ (95% CI) Experienced CLE urologists 90% 0.80 (0.45 1.00) 74% 0.46 (0.10 0.81) 90% 0.80 (0.45 1.00) Novice CLE urologists 77% 0.55 (0.46 0.64) 78% 0.54 (0.45 0.63) 80% 0.59 (0.50 0.68) Pathologists 81% 0.61 (0.47 0.76) - - - - Nonclinical researchers 77% 0.49 (0.38 0.60) - - - - Diagnostic Accuracy Sn Sp Sn Sp Sn Sp Experienced CLE urologists 84% 88% 89% 83% 89% 88% Novice CLE urologists 75% 81% 86% 79% 89% 83% Pathologists 84% 81% - - - - Nonclinical researchers 89% 73% - - - - pa = percent agreement; Sn = sensitivity; Sp = specificity Assess interobserver agreement and learning curve Urologists and nonurologists (n=10) 1-hour computer-based training n=32 patients Moderate agreement: κ= 0.55 Diagnostic accuracy of WLC + CLE Sensitivity 89% Specificity 88% Chang et al. J Endourol. 2013 May;27(5):598-603

Endomicroscopy of the resection bed following BLC-assisted TUR Chang et al. AUA 2017

Endomicroscopy - Upper Tract Bui et al. (2015) J. Endourol. 29:1418 Villa et al. (2016) J. Endourol. 30:237.

ENDOMICROSCOPY - UPPER TRACT n=14 IV fluorescein 0.85 mm probe URS manipulation not significantly impaired Imaging-pathological correlation Bui et al. (2015) J. Endourol. 29:1418

ENDOMICROSCOPY - UPPER TRACT Bui et al. (2015) J. Endourol. 29:1418

Endomicroscopy in Upper Tract n=11 topical fluorescein 0.85 mm probe in working channel of flexible URS Imaging followed by biopsy and laser ablation LG (7), HG (3), inflammation (1) Villa et al. (2016) J. Endourol. 30:237.

Goals: feasibility study develop imaging protocol description of imaging features n=21 in vivo/ex vivo imaging Prostatic and peri-prostatic structures Pathological correlation Vessel Adipocytes Nerve Lopez et al. (2016) J. Urol. 195:1110

Surgical margin assessment: extracapsular extension Extracapsular extension (pt3a, Gleason 3+4)

Endomicroscopy for small renal masses Optical diagnosis of SRMs Pilot ex vivo study to establish CLE imaging features Normal AML Benign Cancer n=20 clear cell Topical fluorescein/2.6mm probe oncocytoma papillary En face imaging -> pathological correlation cystic nephroma leiomyoma acquired cystic Su et al. (2016) J. Urol. 195:486.

Emerging areas M O L E C U L A R I M A G I N G C O M P U T E R - A I D E D I M A G E P R O C E S S I N G

Anti-CD47-FITC imaging with confocal endomicroscopy Pan et al., Sci Transl Med 2014;6:260ra148

Lurie et al. 2017 Biomed Opt Express 8:2106 Lurie et al. 2016 Biomed Opt Express 8:4995. 3D bladder reconstruction using standard WLC videos Longitudinal monitoring Optical annotation

Artificial Intelligence

Machine learning for image processing ARTIFICIAL INTELLIGENCE MACHINE LEARNING DEEP LEARNING CONVOLUTIONAL NEURAL NETWORKS (CNNs)

Convolutional Neural Network Dataset 81 subjects; 458 CLE videos 170,712 images 184 Cancer 70 Low grade papillary 91 High grade papillary 23 Carcinoma in situ 274 Benign 167 normal 107 inflammatory/other Collaboration with Stanford Biomedical Informatics GoogLeNet architecture 22 layers Training 80%, Validation 10%, Testing 10% Chang et al. EUS 2017 Szegedy C, et al. Proceedings of the IEEE Conference on Computer Vision and Pattern Recognition, 2015:1-9

Results Diagnostic Accuracy of CLE 100% 80% 87% 79% 90% 60% 40% 20% 0% Accuracy Sensitivity Specificity Machine

Results Diagnostic Accuracy of CLE 100% 80% 87% 79% 79% 77% 90% 82% 60% 40% 20% 0% Accuracy Sensitivity Specificity Machine Urologists (n=8)

Real-time Feedback

High Grade Tumor

Summary confocal endomicroscopy in urology Platform technology that enables real time optical biopsy Bladder, upper tract, prostate, small renal masses Bladder and UTUC most promising Real time differentiation of cancer and benign, cancer grade (?) May improve yield of positive biopsy Combination with other enhanced endoscopy technologies Improve the quality of primary endoscopic intervention Current Limitations Single center experiences Going beyond initial proof-of-concept Clinical impact unknown Image interpretation Future Multi-center validation Molecular imaging Machine learning (convolutional neural network) for real time image processing

Acknowledgements Liao Lab Kathy Mach Tim Chang Bernhard Kiss Gautier Marcq Mandy Sin Ying Pan Dharti Trivedi Ying Pan Kristen Lurie Dimi Zlatev Timothy Chang Tommy Metzner Aristeo Lopez Mark Hsu Mandy Sin Emanuela Altobelli Michael Davenport Stephanie Chen Melanie Ngan Jen-Jane Liu Ruchika Mohan Lei Kang Collaborators Irv Weissman Eila Skinner Phil Beachy Sam Gambhir John Leppert Robert Rouse Audrey Ellerbee Zhen Cheng Funding NIH/NCI R01 CA 160986 Stanford Cancer Institute Urology Care Foundation NIH/NIAID U01 AI 082457 NIH/NIAID R44 AI 88756